Horizon Therapeutics (DB:HPR) - Cotización, noticias y análisis

Resumen de acción HPR

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Saber más

Análisis fundamental de HPR
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	4/6
Rendimiento pasado	1/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Cotiza un 55.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 24.94%

Análisis de riesgos

Grandes partidas extraordinarias que afectan a los resultados financieros

Los márgenes de beneficio (12%) son inferiores a los del año pasado (20.1%)

Competidores de Horizon Therapeutics Public Limited Company

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€827.2m

Sartorius

XTRA:SRT3

€13.4b

Merck KGaA

XTRA:MRK

€61.6b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Horizon Therapeutics
Precios históricos de las acciones
Precio actual de la acción	US$110.20
Máximo en las últimas 52 semanas	US$110.80
Mínimo de 52 semanas	US$61.68
Beta	1.01
1Cambio en 1 mes	3.38%
Variación en 3 meses	17.86%
Cambio de 1 año	67.30%
3Variación en 3 años	54.28%
Variación en 5 años	601.91%
Variación desde la OPV	1,783.76%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	HPR	DE Biotechs	Mercado DE
7D	-0.2%	-0.7%	0.2%
1Y	67.3%	-17.2%	8.5%

Rentabilidad vs. Industria: HPR superó a la industria German Biotechs, que obtuvo un rendimiento del -17.2% el año pasado.

Rentabilidad vs. Mercado: HPR superó al mercado German, que obtuvo un rendimiento del 8.5% el año pasado.

Volatilidad de los precios

Is HPR's price volatile compared to industry and market?
HPR volatility
HPR Average Weekly Movement	2.8%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Precio estable de las acciones: HPR no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de HPR (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2005	2,190	Tim Walbert	www.horizontherapeutics.com

Resumen de fundamentos de Horizon Therapeutics Public Limited Company

¿Cómo se comparan los beneficios e ingresos de Horizon Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de HPR
Capitalización bursátil	€25.30b
Beneficios(TTM)	€416.06m
Ingresos (TTM)	€3.46b

60.8x

Ratio precio-beneficio (PE)

7.3x

Ratio precio-ventas (PS)

¿Está HPR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HPR
Ingresos	US$3.64b
Coste de los ingresos	US$824.98m
Beneficio bruto	US$2.82b
Otros gastos	US$2.38b
Beneficios	US$438.00m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	1.91
Margen bruto	77.36%
Margen de beneficio neto	12.02%
Ratio deuda/patrimonio	48.2%

¿Cómo se ha desempeñado HPR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción HPR

Recompensas

Análisis de riesgos

Competidores de Horizon Therapeutics Public Limited Company

XTRA:BIO3

€1.4b

XTRA:FYB

€827.2m

XTRA:SRT3

€13.4b

XTRA:MRK

€61.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

Insufficient new directors

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Third quarter 2022 earnings released: EPS: US$0.59 (vs US$1.44 in 3Q 2021)

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.70 in 2Q 2021)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil

Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials

Horizon Therapeutics plc Announces Analysis from the Phase 3 N-Momentum Study Demonstrates the Effectiveness of Uplizna(R) (Inebilizumab-Cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (Hzn-7734) for the Treatment of Alopecia Areata

First quarter 2022 earnings released: EPS: US$0.89 (vs US$0.55 loss in 1Q 2021)

Horizon Therapeutics Public Limited Company Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Receives European Commission Approval of Uplizna (Inebilizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Insufficient new directors

Horizon Therapeutics Public Limited Company to Report Q1, 2022 Results on May 04, 2022

Horizon Therapeutics plc Announces Presentation of A Post-Hoc Analysis from the N-Momentum Phase 3 Pivotal Trial of UPLIZNA

Insider recently sold €3.1m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)